HighLight Capital
HighLight reaches first close on third renminbi vehicle
Chinese healthcare-focused GP HighLight Capital, which was set up by Steven Wang, formerly of CDH Investments, has reached the first close for its third renminbi vehicle at around 70% of the hard cap.
Sequoia, HighLight lead $80m round for China's BrightGene
Sequoia Capital China and HighLight Capital have led a RMB550 million ($80 million) pre-IPO funding round for BrightGene Bio-Medical Technology, a Chinese developer of innovative and generic drugs. An investment unit of GF Securities also participated.
China's HighLight to exit US-based biotech player Bonti
Chinese healthcare-focused GP HighLight Capital is set to exit its position in US-based biotechnology company Bonti after Allergan agreed to acquire the business for $195 million, plus additional payments if certain development targets are met.
China biotech: Finding the formula
An eruption of investment and company creation in Chinese biotech has signaled the dawn of a raw but promising market. First-movers must negotiate immediate pitfalls while targeting long-term upside
Hong Kong technology IPOs: Size matters
Hong Kong has altered its IPO regime to attract tech companies with unorthodox shareholding structures and biotech start-ups with no revenue. But only certain businesses are welcome to apply
Fund focus: HighLight’s early-stage prescription
HighLight Capital has secured $250 million for its second China healthcare-focused fund, suggesting that proven sector specialists are getting traction with institutional LPs
China's HighLight Capital closes Fund II at $250m
Chinese healthcare-focused GP HighLight Capital, which was set up by former CDH Investments executive Steven Wang, has closed its second US dollar-denominated fund at the hard cap of $250 million.